Research programme: cancer therapeutics - Bluebird Bio/Celgene

Drug Profile

Research programme: cancer therapeutics - Bluebird Bio/Celgene

Alternative Names: Anti-BCMA CAR T-cells

Latest Information Update: 08 May 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator bluebird bio
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple myeloma

Most Recent Events

  • 15 Mar 2017 Blubird Bio plans a phase I trial of bb 21217 (CRB-402) for Cancer (Blubird Bio Form 10-K, March 2017).
  • 16 Apr 2016 Pharmacodynamics data from a preclinical study presented at the 107th Annual meeting of the American Association of Cancer Research (AACR-2016)
  • 06 Dec 2015 Pharmacodynamics data from preclinical trials in Multiple myeloma released by Bluebird Bio (9188610; 9187079)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top